Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 22:2:733492.
doi: 10.3389/ffunb.2021.733492. eCollection 2021.

Yeasts as Biopharmaceutical Production Platforms

Natalja Kulagina  1 , Sébastien Besseau  1 , Charlotte Godon  2 , Gustavo H Goldman  3 , Nicolas Papon  2 , Vincent Courdavault  1
Affiliations

Yeasts as Biopharmaceutical Production Platforms

Natalja Kulagina et al. Front Fungal Biol. .
No abstract available

Keywords: biopharmaceuticals; heterologous production; metabolic engineering; natural products; yeast.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Yeast platforms expressing heterologous genes. (A) Yeast cells producing biopharmaceuticals. Few heterologous genes are required to produce recombinant proteins of interest. In some cases, several genes are necessary (e.g., multiple gene copies, fusion proteins, Hb, glycosylation humanization). (B) Yeast cells producing NPs. Multiple heterologous genes are introduced into yeast to reconstitute the entire metabolic pathways and produce the compounds of interest, or their precursors.
See this image and copyright information in PMC

References

    1. Berraondo P., Sanmamed M. F., Ochoa M. C., Etxeberria I., Aznar M. A., Pérez-Gracia J. L., et al. . (2019). Cytokines in clinical cancer immunotherapy. Br. J. Cancer 120, 6–15. 10.1038/s41416-018-0328-y - DOI - PMC - PubMed
    1. Bobrowicz P., Davidson R. C., Li H., Potgieter T. I., Nett J. H., Hamilton S. R., et al. . (2004). Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology 14, 757–766. 10.1093/glycob/cwh104 - DOI - PubMed
    1. Brown S., Clastre M., Courdavault V., O'Connor S. E. (2015). De novo production of the plant-derived alkaloid strictosidine in yeast. Proc. Natl. Acad. Sci. U. S. A. 112, 3205–3210. 10.1073/pnas.1423555112 - DOI - PMC - PubMed
    1. Buss N. A. P. S., Henderson S. J., McFarlane M., Shenton J. M., De Haan L. (2012). Monoclonal antibody therapeutics: history and future. Curr. Opin. Pharmacol. 12, 615–622. 10.1016/j.coph.2012.08.001 - DOI - PubMed
    1. Cardenas G. A., Deitcher S. R. (2005). Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin. Proc. 80, 491–493. 10.4065/80.4.491 - DOI - PubMed

LinkOut - more resources